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RotaTeq® on elävä, oraalisesti kolmesti (2, 3 ja 5 kk) annosteltava rotavirusrokote, joka koostuu 
ihmisen ja naudan rotavirusten yhdistelmistä. Villityypin rotavirusten tapaan myös rokotetyypin 
viruksien on havaittu erittyvän ja muodostavan uusia kombinaatioita rokotteen sisältämien kantojen 
välillä.  
Tutkimuksen tarkoituksena oli tutkia rokotetyypin rotaviruksen erityksen yleisyyttä lapsilla. 
Aineistona käytettiin Tampereen yliopistollisessa sairaalassa syyskuun 2009 ja elokuun 2011 
välisenä aikana hoidettuja ripulitautia (AGE) tai hengitystieinfektiota (RTI) sairastavia lapsia, joilta 
kerättiin ulostenäyte. Tutkimukseemme osallistui 333 lasta, jotka olivat saaneet vähintään yhden 
annoksen RotaTeq® rokotetta. Lapset jaettiin tutkimusryhmiin taudin diagnoosin perusteella: 182 
RTI, 56 AGE, ja 62 lapsella oli molempien oireita. Ulostenäytteistä tutkittiin PCR-menetelmällä 
rotaviruksen pintaproteiinit VP7, VP4 ja VP6 mahdollisen rokoteviruksen tunnistamiseksi. 
Rokoteperäisiä yhdistelmäviruksia yritettiin kasvattaa soluviljelmissä. 
Tutkimuksessamme RotaTeq® rokoteviruksen erittyminen oli yleistä, 17 %:lla (49) lapsista 
havaittiin RotaTeq® VP7 ulosteesta. Näistä 30 lapsella oli RTI, 12 AGE ja 7 molempia oireita. 
RotaTeq® G1 oli yleisin genotyyppi kaikissa ryhmissä. Erityksen kestoa tutkittiin RTI lapsilla, joita 
pidimme terveiden verrokkeina. Eritystä havaittiin 14/28 (50 %) näytteistä, jotka oli otettu 1. ja 2. 
rokoteannoksen välissä, 10/38 (26 %) 2. ja 3. annoksen välissä, ja 6/117 (5 %) 3. rokoteannoksen 
saaneiden näytteistä. On kuitenkin mahdollista, että erittyminen on alkanut jo ensimmäisen 
rokoteannoksen jälkeen, joten todellisuudessa erityksen kesto voi olla havaittua pidempi. 
Tutkimuksessa havaitsimme, että RotaTeq® rokotevirusten erittyminen on yleistä myös lapsilla, 
joilla ei ole gastroenteriitin oireita. Pitkään jatkuva virusten erittyminen ja täten myöskin 
lisääntyminen suolistossa viittaa pitkittyneeseen, jopa krooniseen infektioon. Löydöksen kliininen 
merkitys on kuitenkin epäselvä ja vaatii lisätutkimuksia.  
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Introduction 
Rotavirus (RV) is globally the most common cause of acute gastroenteritis (AGE) in young children 
with an estimated death toll of 453.000 annually 1. In developed countries RV is an important 
cause of hospitalizations. Two live oral RV vaccines were licensed in 2006 2, 3, and many countries 
have introduced universal RV vaccination programs. 
RotaTeq® (Merck & Co., Whitehouse Station, NJ, USA) is a live oral pentavalent human-bovine 
reassortant RV vaccine, consisting of five vaccine viruses, each with bovine RV strain WC-3 
(G6P[5]) backbone reassorted with either VP7 surface proteins of human RVs G1, G2, G3 and G4, 
or with human VP4 outer surface protein P[8]. In Finland, RotaTeq® vaccine was taken into the 
national immunization program in September 2009, and is administered on a three dose schedule 
at the ages of 2, 3 and 5 months. The coverage is over 95 %, and the impact of RotaTeq® 
vaccinations on RV gastroenteritis (RVGE) seen in hospital in Finland has been impressive with 91 
% reduction in vaccine eligible age groups 4, 5. 
In wild-type RVGE, shedding of RV in stools usually lasts for 7-10 days 6. Prolonged shedding of 
wild-type RV has been described up to 57 days after hospital admission for RVGE in previously 
healthy children, and up to 25 days in asymptomatic children 7, 8. Shedding of RotaTeq® vaccine 
strain viruses was reported to be low in pre-licensure studies3, because the testing method, the 
plaque assay in cell culture, was insensitive. In the REST study, using the plaque assay, the rate of 
shedding of RotaTeq® vaccine virus was 32/360 (8.9 %) after the first dose, 0/249 after the second 
dose and 1/385 (0.3 %) after the third dose, and the duration of shedding was 1-15 days with peak 
from 4 to 6 days.9 Considerably higher rates of vaccine virus shedding were recently detected 
when the REST study samples were re-examined with enzyme-linked immunosorbent assay 
(ELISA) and VP6 reverse transcription polymerase chain reaction (RT-PCR) 10. 
Other recent studies using ELISA to detect RV antigen have shown shedding rates of RotaTeq® 
vaccine viruses up to 21.4 % in vaccinated children, who have had AGE symptoms after 
vaccination 11, 12. A study by Hsieh et al. used real-time polymerase chain reaction (qPCR) for 
detection of RV RNA, and found very high rates of shedding (80-90 %) after the first dose, while 
the corresponding rate of shedding using ELISA antigen detection was 20-30 %. The maximum 
duration of shedding was 28 days, after the first dose.13 Prolonged shedding and transmission of 
RotaTeq® vaccine viruses have been reported in premature infants and children with severe 
combined immunodeficiency (SCID) and, occasionally, in immunocompetent children 14-17.  
Several studies on children have detected presence of vaccine-derived double-reassortant RV 
G1P[8] (vdG1P[8]) in the stools in association with AGE symptoms 11, 16-19, suggesting that 
vdG1P[8] may be of greater virulence than the original vaccine strains. Shedding of vdG1P[8] has 
also been associated with sibling transmission 16. 
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We examined the occasional presence of RotaTeq® vaccine viruses in young children seen in 
hospital mainly for respiratory tract infection (RTI) and correlated these findings with history of RV 
vaccination. This approach yielded new information on the extent, duration, and type of RotaTeq® 
vaccine virus shedding. 
 
Materials and methods 
Clinical methods 
A prospective study on the etiology of AGE and RTI in children was conducted at Tampere 
University Hospital from September 1, 2009 to August 31, 2011. The study was approved by the 
Ethics Committee of Pirkanmaa Hospital District. A written consent of a parent or legal guardian 
was obtained before enrollment of the child into the study.20 Children, who were seen in the 
pediatric outpatient clinic or admitted into the pediatric ward with AGE or who were admitted into 
the pediatric ward with RTI, were eligible for the study. Many children actually had symptoms of 
both AGE and RTI. Patients with nosocomial AGE were also included.5, 20 
Information about possible RV vaccination was enquired from the parents and confirmed from the 
records of the respective well baby clinic by a study nurse. A stool sample was collected during the 
hospitalization or, if not successful, the parents were provided with a sample kit to send a stool 
specimen within two weeks from home. 
Laboratory methods 
Viral RNA was extracted from stool samples using Qiagen QIAamp Viral RNA Mini Kit (Hilden, 
Germany) according to the manufacturer’s instructions. The RNA extracts were stored in a freezer 
at -70°C until tested by RT-PCR for RV. RV VP7 and VP4 sequences were detected using 
previously described primers and methods 21-22. VP6 sequences were detected as previously 
described 19, 23.  
Positive RT-PCR detections were further analyzed by sequencing using the same primers as in 
RT-PCR. Positive amplicons (VP7, VP4 and VP6) were purified using Qiagen QIAquick Gel 
Extraction Kit (Hilden, Germany) and sequenced using BigDye Terminator v1.1 Cycle Sequencing 
Ready Reaction Kit with AmpliTaq DNA Polymerase FS (Applied Biosystems, Foster City, CA) on 
an ABI PRISMTM 310 Genetic Analyzer. Sequences were analyzed with SequencherTM 4.9 and 
compared with published reference strains from GeneBank (http://www.ncbi.nlm.nih.gov/BLAST/, 
Nucleotide blast). 
RV VP6 antigen was determined from RotaTeq® VP7 positive stool samples by ELISA, using the 
IDEIA Rotavirus Kit (Oxoid Ltd, Basingstoke, Hampshire, United Kingdom). Stools absorbed in a 
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diaper were not tested by ELISA, as the test could not be performed reliably. A sample with an 
optical density read >0.15 by spectrophotometry at a wavelength of 450 nm was considered as 
positive. Positive stool samples were propagated in MA104 cells as described previously with the 
modification of using minimum essential medium (MEM) with 0.5 µg/mL of trypsin instead of MEM 
containing 100 U/mL penicillin, 100 U/mL L-glutamine and 100 µg/mL streptomycin 24.  
 
Results 
During the two-year study period a total of 1610 children with symptoms of AGE, RTI, or both, were 
recruited into the study and 1002 (62.2 %) children provided stool samples. Of these children, 333 
(33.2 %) had been vaccinated with RotaTeq® at any time after September 1, 2009 and formed the 
patient material of our study. Of the 333 children, 56 (16.8 %) were seen or admitted for AGE, 182 
(54.7 %) were admitted for RTI, and 95 (28.5 %) had both AGE and RTI symptoms during the clinic 
visit or hospital stay. The mean age of the study population was 258 days, ranging from 56 to 643 
days; 70.6 % were males. 
RV detection and types 
Out of the 333 stool samples from children who had ever been vaccinated with RotaTeq® vaccine, 
53 (15.9 %) were RV positive by RT-PCR specific for VP7. Four (7.5 %) were identified as wild-
type RVs and 49 (92.5 %) as RotaTeq® vaccine type RVs by sequence analysis of VP7. All 4 wild-
type associated cases occurred in children who were hospitalized with AGE or a combination of 
AGE and RTI symptoms, and the wild-type RV genotypes were G4P[8] (3 cases) or G9P[8] (1 
case). Of those children, 3 had received the full vaccine regimen and one had received one dose 
of RotaTeq® vaccine. It is assumed that these cases were breakthrough RV infections in 
vaccinated children. No vaccine-type virus was detected concomitantly with the wild-type RV in 
these cases.  
Of the 49 vaccine strain positive children 12 (24.5 %) had AGE, 30 (61.2 %) had RTI, and 7 (14.3 
%) had both AGE and RTI symptoms. RV antigen by ELISA was tested from 30 (61.2 %) of the 49 
VP7 positive cases. ELISA could not be performed from the remaining 19 samples due to an 
insufficient amount or type of the sample (diaper). Out of those 30 samples, only 5 (16.7 %) were 
ELISA positive; of these 1 was from a child with AGE and 4 from children with RTI. The ELISA 
positive child with AGE was detected with RotaTeq® G1P[8] as did all the 4 children with RTI, one 
child was also detected with additional P[5] VP4. 
VP6 RT-PCR was positive in 47 (95.9 %) and negative in 2 (4.1 %) of the 49 vaccine VP7 positive 
cases. The negative results were from one child with RTI and another child with AGE. Bovine 
vaccine type VP6 was detected in 46 cases and human type P[8] VP6 in 1 child with RTI, 
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described later. VP6 RT-PCR was negative in 2 cases. VP4 RT-PCR was positive in 35 and 
negative in 14 cases.  
RotaTeq® G1 was by far the most common G-type as it was detected in 46 of the 49 vaccine type 
VP7 positive cases. Of these, 30 children had RTI. The combination G1P[8] was detected in 11 
children (36.7 %) (once concomitantly with RotaTeq® G6). G1P[5] was detected in 4 children (13.3 
%), and one child had RotaTeq® G1 with both P[5] and P[8]. VP4 reassortant G6P[8] was detected 
in two children with RTI symptoms, and one child, mentioned above and described later, was 
detected with human VP6 reassorted with RotaTeq® G1 and human P[8].  (Fig 1) 
Genotypic distribution of vaccine origin RVs in children with AGE (N=12) was even more diverse 
than in children with RTI. Double-reassortant G1P[8] was detected in 4 children (33.3 %). 
RotaTeq® G1 with P[5] and P[8] was found in the stools of two children (16.7 %). Other genotypes 
were detected only one each and are shown in Figure 1. 
In children with both AGE and RTI symptoms (N=7) RotaTeq® G1 alone, RotaTeq® G1P[8] and 
RotaTeq® G1 with P[5] and P[8] were detected in two children each. One child was detected with 
RotaTeq® G1P[5]. (Fig. 1) 
 
Figure 1. Genotypic distribution of children detected with RotaTeq® vaccine strains detected in stool samples of children 
with respiratory tract infection (RTI), acute gastroenteritis (AGE), or both. 
One child hospitalized for RTI was detected with RotaTeq® vaccine origin VP7, together with 
human wild-type VP4 and VP6. The stool sample of this child was obtained 10 days after the 
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second dose of RotaTeq® vaccine. The sample was extracted for several times, and RT-PCR and 
sequencing were done twice for each protein from each extraction, but the RT-PCR and 
sequencing results remained identical. The sample could not be propagated in MA104 cells. 
Vaccine-derived G1P[8] double-reassortants 
Sixteen (32.7 %) children out of 49 were detected concomitantly with vaccine-derived VP7 G1 and 
VP4 P[8] and bovine VP6 of vaccine origin. In 4 cases the virus had already been verified as true 
double-reassortant rather than only concomitant shedding of vaccine originated proteins. These 4 
children with AGE symptoms and RotaTeq® G1P[8] double-reassortant virus have been previously 
reported 19. In the remaining 12 cases, the same vaccine-derived G1P[8] (vdG1P[8]) rotavirus was 
now detected in 10 children with RTI and in 2 children with AGE and RTI symptoms. 
Stool samples of three children detected with RotaTeq® vdG1P[8], who had recently received the 
first dose of RotaTeq® vaccine and were ELISA positive, were cultured in MA104 cells. Stool 
samples were obtained 6 days (1 case) and 14 days (2 cases) after the vaccination. Two of the 
samples showed no sign of growth in cell culture, but in one case (sample obtained 6 days after 
vaccination), the virus was successfully propagated and remained stable in three passages of cell 
culture.   
Shedding of RotaTeq® vaccine viruses in children with RTI 
Of the 182 children with RTI, 28 had received the 1st dose, 38 had received two doses and 116 
had received all three doses of RotaTeq® vaccine at the time they were hospitalized for RTI. In 
these children, shedding of RotaTeq® vaccine virus was detected in 14/28 (50.0 %) after the first 
and before the second dose. After the second and before the third dose vaccine virus shedding 
was detected in 10/38 cases (26.3 %), and after the third dose 6 out of 116 cases (5.2 %). The 
oldest child with RotaTeq® vaccine virus detection was aged 8 months. The age distribution of the 
children is shown in Figure 2. 
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Figure 2. Age distribution of children hospitalized with respiratory tract infections and studied for RotaTeq® vaccine 
strains in stool samples. 
Overall, RotaTeq® vdG1P[8] was commonly shed after each dose of the vaccine. After the first 
dose 7 children (50.0 %) shed RotaTeq® vdG1P[8] and 3 children G1 alone. After the second and 
the third dose of vdG1P[8] was less commonly found but RotaTeq® G1 was the most common 
genotype as it was detected in various combinations in 5 children (50.0 %) and in 3 children (50.0 
%) after these doses, respectively. No other vaccine-derived human G-type but G1 was found in 
the samples collected from children with RTI. The vaccine strains and combinations in relation to 
the latest vaccine dose are shown in Table 1. 
Genotype I dose (N=14) II dose (N=10) III dose (N=6) Total (N=30) 
G1 3 (21.4) 5 (50.0) 3 (50.0) 11 (36.7) 
vdG1P[8] 7 (50.0) 2 (20.0) 1 (16.7) 10 (33.3) 
G1P[5] 1 (7.1) 2 (20.0) 1 (16.7) 4 (13.3) 
G1+P[5]+P[8] 1 (7.1) 0 0 1 (3.3) 
G1+Human P[8] 0 1 (10.0) 0 1 (3.3) 
G6P[8] 1 (7.1) 0 1 (16.7) 2 (6.7) 
G1+G6+P[8] 1 (7.1) 0 0 1 (3.3) 
Table 1. Frequency, N (%), of rotavirus genotypes and their combinations detected after each dose of RotaTeq® vaccine 
in children hospitalized with respiratory infection. 
 
The duration of shedding was counted from the date of the most recent vaccine dose and was over 
14 days in 16 cases (53.3 %) and over 30 days in 9 cases (30.0 %). The median duration of 
shedding of RotaTeq® G1 containing vaccine strains, excluding the vdG1P[8] and concomitant 
shedding of G6P[8], was 22 days. The median duration of shedding of RotaTeq® vdG1P[8] was 14 
days. The longest duration of shedding was 84 days counted from the third immunization in a child 
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detected with RotaTeq® G1 VP7, however VP4 and VP6 RT-PCRs were negative. The proportion 
of long-time (over 14 days) shedders became larger after each dose of vaccine received; after the 
first dose prolonged shedding was detected in 4/14 (28.6 %) children, respectively after the second 
7/10 (70.0 %) and after the third dose 5/6 (83.3 %).  
 
Discussion 
In this study, we used children hospitalized for respiratory infection without AGE symptoms as 
proxies for healthy children to follow the shedding of RotaTeq® vaccine viruses. Among this 
pediatruc population, we detected the presence of RotaTeq® vaccine viruses in 16.5 %. This is 
higher than detected in  the pre-licensure studies using the plaque assay method on samples 
collected within a week after each dose 3, 9, 25, but largely in line with more recent studies, which 
have shown shedding rates of around 20 % using RT-PCR or EIA as detection methods 11, 12, 26. 
However, these studies were originally planned to detect RV soon after vaccination, whereas our 
study was an occasional survey of children seen in hospital and included many who had received 
the vaccine a long time before hospitalization.  
The previous studies have not detected prolonged shedding in such scale; although Hsieh et al. 
detected RotaTeq® strains 28 days after inoculation 13. Very long shedding, like our finding, up to 
the age of 8 months has not been described previously, although Patel et al. detected shedding 
over 200 days in immunocompromised children 15. We detected that the proportion of prolonged 
shedding became higher after each dose of RotaTeq® vaccine. However, it is not certain after 
which dose the shedding started in such cases. It is possible that our occasional sampling detected 
children who became long time shedders already after the first dose.  
Dominance of RotaTeq® G1 genotype in shedding was a new finding, as G1 alone, G1P[5] or 
vdG1P[8] were detected in the stool samples of 85.7 % of all children and 90.0 % of children with 
RTI symptoms. In pre-licensure studies of RotaTeq®, G1 and P[8] were also the most common 
genotypes to be shed after vaccination, also shedding of vdG1P[8] was detected already in these 
studies 27, 28. In the composition of RotaTeq® vaccine, the amount of G1 and P[8] is nearly the 
same as the amount of G3 and G4, and lower than G2; therefore the higher shedding rate of 
RotaTeq® G1 cannot be explained by a higher inoculum 29. Our study showed that the only 
unifying factor with prolonged shedding was RotaTeq® G1 VP7, and detected long duration of 
shedding of G1 whether the VP4 was P[5] or P[8]. The properties that make G1 such a 
predominant genotype in shedding remain unknown and need further study.  
We also detected a high number, 16 in total, of children, who were shedding either vaccine-derived 
double-reassortant G1P[8] RVs or at least G1 and P[8] proteins of the vaccine viruses 
concomitantly. Of these, 4 cases of vdG1P[8] have been previously confirmed by cell culture as 
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stable double-reassortant RVs with the ability to cause AGE symptoms in children either after the 
first or the second dose of RotaTeq® vaccine within 14 days19. In this study we confirmed one 
ELISA positive vdG1P[8] double-reassortant RV case by cell culture in a child, who had received 
the first dose of RotaTeq® vaccine 6 days before hospital admission caused by RTI with no 
diarrhea. We cultured two other ELISA positive RTI cases in MA104 cells but no growth was 
detected. The other 9 cases were ELISA negative and were not cultured. Therefore we cannot 
confirm whether these detections are true vdG1P[8] double-reassortants or concomitant shedding 
of G1 and P[8] vaccine virus proteins but believe the former is more likely. Still, and if so, our 
finding of vdG1P[8] double-reassortants in asymptomatic children suggests that the double-
reassortant is not always associated with diarrheal symptoms. However, we could not verify if 
these children had had AGE symptoms soon after the vaccination and before hospital admission, 
because we could not obtain a full medical history of these children. The potential of the vdG1P[8] 
to cause symptoms may still be higher than that of other vaccine-derived viruses, and there is a 
possibility that the double-reassortant is more infectious than other reassortants. 
The major limitation of our study was the design of the original study, which was not planned to 
determine the rate or duration of shedding of RotaTeq® vaccine, but only provided stool samples 
at random time points. However, even with this less than optimal study design we could determine 
that long term shedding of vaccine viruses is not uncommon. While we could not determine after 
which dose the long-term shedding started, it is reasonable to speculate that already the first dose 
may select those individuals who eventually become long-term shedders. 
Shedding of RV vaccine strains in asymptomatic children is usually not regarded as clinically 
significant, with the possible exception of transmission to susceptible or immunocompromised 
contacts. The use of sensitive RT-PCR in detection of vaccine viruses has been criticized, and the 
plaque assay in cell culture defended, on the grounds that RT-PCR may not detect live infectious 
viruses but only parts (RNA) of the virus 10. However, a prolonged presence and multiplication of 
the vaccine viruses in the intestines even as detected by RT-PCR in this study is an indication of 
chronic infection in the intestines and may also be associated with clinical consequences, although 
these are unknown as yet. 
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